# Value of adding 0.01% atropine with orthokeratology for myopia in children: an updated meta-analysis of randomized controlled trials

**Authors:** Shudan Tu, Huangfang Ying, Liyang Ni, Zilong Zhang, Weiping Hu

PMC · DOI: 10.3389/fped.2025.1571790 · 2025-06-03

## TL;DR

Adding 0.01% atropine to orthokeratology slows myopia progression in children more than orthokeratology alone.

## Contribution

This study provides an updated meta-analysis showing the added benefit of 0.01% atropine with orthokeratology for myopia control.

## Key findings

- AOK significantly reduced axial length progression at 6, 12, and 24 months compared to OK alone.
- AOK increased pupil diameter but did not significantly affect spherical equivalent refraction or intraocular pressure.
- AOK showed a tendency to reduce amplitude of accommodation, though results were not statistically significant.

## Abstract

This systematic review and meta-analysis aimed to compare outcomes of 0.01% atropine with orthokeratology (AOK) vs. orthokeratology (OK) alone for slowing the progression of myopia in children.

MEDLINE via PubMed, Embase, Scopus, Web of Science, CENTRAL (Cochrane Central Register of Controlled Trials), Chinese electronic databases of VIP, and Wanfang were searched from inception until 19th August 2024 for randomized controlled trials (RCTs) about the review topic. The primary outcome was a change in axial length (AL) (mm). Secondary outcomes were spherical equivalent refraction (SER) (Diopter), pupil diameter (PD) (mm), amplitude of accommodation (AA) (Diopter), and intraocular pressure (IOP) (mmHg).

10 articles corresponding to eight RCTs were included. Meta-analysis found that change in AL was significantly reduced with AOK as compared to OK alone at 6 months (MD: −0.10 95% CI: −0.14, −0.06 I2 = 48%), 12 months (MD: −0.08 95% CI: −0.10, −0.07 I2 = 0%) and 24 months (MD: −0.14 95% CI: −0.19, −0.08 I2 = 0%). Pooled analysis found that AOK did not reduce the progression of SER (MD: 0.06 95% CI: −0.00, 0.12 I2 = 7%) and increased PD (MD: 0.63 95% CI: 0.40, 0.85 I2 = 86%) as compared to OK alone. Pooled analysis also found a tendency of reduced AA with AOK as compared to OK alone but without significant results (MD: −0.45 95% CI: −1.00, 0.10 I2 = 59%). Meta-analysis failed to show a statistically significant difference in change of IOP between AOK and OK (MD: −0.49 95% CI: −1.48, 0.50 I2 = 51%).

AOK seems to be more efficacious in slowing the progression of myopia in children as compared to OK alone.

## Linked entities

- **Chemicals:** atropine (PubChem CID 3661)
- **Diseases:** myopia (MONDO:0001384)

## Full-text entities

- **Diseases:** myopia (MESH:D009216)
- **Chemicals:** atropine (MESH:D001285)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12170616/full.md

---
Source: https://tomesphere.com/paper/PMC12170616